文献速递神经肿瘤神经重症

出血性转移性脑恶性肿瘤的预测因素与手术结局

Predictors and surgical outcome of hemorrhagic metastatic brain malignancies.
PubMed 文献 · J Neurooncol · 2024-05-27

回顾性单中心研究纳入229例2016年1月至2017年12月间接受脑转移瘤切除的患者,比较出血性与非出血性转移瘤。黑色素瘤转移与术前出血显著相关(p=0.001),术前抗凝药使用未增加出血风险(p=0.592),停用抗凝药后手术未显著影响术中失血、手术时长或术后再出血风险(p>0.096),但瘤内出血与总生存期缩短相关(p=0.001)。

要点

  • 黑色素瘤转移与术前出血显著相关(p=0.001)。
  • 术前抗凝药使用未增加出血风险(p=0.592)。
  • 瘤内出血与总生存期缩短相关(p=0.001)。

核心结论

  • 研究强调脑转移瘤患者抗凝治疗的安全性,以及出血性转移瘤患者在暂时停用抗凝药后接受神经外科治疗的安全性。
  • 瘤内出血对生存有负面影响,突显其在脑转移瘤患者中的预后意义。
  • 需要更大队列的进一步研究来验证这些发现并阐明潜在机制。

研究设计与样本

  • 回顾性单中心病历回顾,纳入2016年1月至2017年12月间接受脑转移瘤切除的患者,共229例符合纳入标准。
  • 比较出血性脑转移瘤与非出血性脑转移瘤患者,收集并分析术前预测因素、围手术期管理和术后结局数据。

主要发现

  • 黑色素瘤转移与术前出血显著相关,校正混杂因素后仍显著(p=0.001)。
  • 不良临床状态(p=0.001)、较大肿瘤体积(p=0.020)和不良预后(p=0.001)独立预测自发性出血。
  • 术前使用抗凝药物与出血风险增加无关(p=0.592)。
  • 停用抗凝药后手术切除出血性脑转移瘤未显著影响术中失血量、手术时长或术后再出血风险(p>0.096)。
  • 瘤内出血与总生存期缩短相关(p=0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Intracerebral metastases present a substantial risk of tumor-associated intracerebral hemorrhage (ICH). This study aimed to investigate the risk of hemorrhagic events in brain metastases (BM) from various primary tumor sites and evaluate the safety and outcomes of surgical tumor removal. METHODS: A retrospective, single-center review of medical records was conducted for patients who underwent BM removal between January 2016 and December 2017. Patients with hemorrhagic BM were compared to those with non-hemorrhagic BM. Data on preoperative predictors, perioperative management, and postoperative outcomes were collected and analyzed. RESULTS: A total of 229 patients met the inclusion criteria. Melanoma metastases were significantly associated with preoperative hemorrhage, even after adjusting for confounding factors (p = 0.001). Poor clinical status (p = 0.001), larger tumor volume (p = 0.020), and unfavorable prognosis (p = 0.001) independently predicted spontaneous hemorrhage. Importantly, preoperative use of anticoagulant medications was not linked to increased hemorrhagic risk (p = 0.592). Surgical removal of hemorrhagic BM, following cessation of blood-thinning medication, did not significantly affect intraoperative blood loss, surgical duration, or postoperative rebleeding risk (p > 0.096). However, intra-tumoral hemorrhage was associated with reduced overall survival (p = 0.001). CONCLUSION: This study emphasizes the safety of anticoagulation in patients with BM and highlights the safety of neurosurgical treatment in patients with hemorrhagic BM when blood-thinning medication is temporarily paused. The presence of intra-tumoral hemorrhage negatively impacts survival, highlighting its prognostic significance in BM patients. Further research with larger cohorts is warranted to validate these findings and elucidate underlying mechanisms.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Rauschenbach L, Kolbe P, Engel A, et al. Predictors and surgical outcome of hemorrhagic metastatic brain malignancies. J Neurooncol. 2024. PMID: 38801490. doi:10.1007/s11060-024-04714-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。